ASA Monitor May 2024, Vol. 88, 27.
AstraZeneca has announced the availability of its inhaled, fixed-dose combination rescue medication Airsupra® (albuterol/budesonide) in the U.S. by prescription, following FDA approval in January 2023. Airsupra is indicated for the as-needed treatment or prevention of asthma symptoms and to prevent sudden severe breathing problems, such as asthma attacks, in adults ages 18 and older. The medication combines a short-acting beta2-agonist (SABA) to relax airway muscles and an inhaled corticosteroid (ICS) to reduce lung inflammation. The 2023 Global Initiative for Asthma (GINA) report recommends a combination of SABA/ICS for asthma rescue therapy for adults, irrespective of ICS maintenance medication, due to the risks associated with SABA-only treatment. Airsupra is the only FDA-approved SABA/ICS rescue inhaler available in the U.S. designed to manage both symptoms and inflammation.
Source: asamonitor.pub/48LPcMo